JP6230443B2 - 近赤外色素結合ヒアルロン酸誘導体およびそれを有する光イメージング用造影剤 - Google Patents

近赤外色素結合ヒアルロン酸誘導体およびそれを有する光イメージング用造影剤 Download PDF

Info

Publication number
JP6230443B2
JP6230443B2 JP2014031227A JP2014031227A JP6230443B2 JP 6230443 B2 JP6230443 B2 JP 6230443B2 JP 2014031227 A JP2014031227 A JP 2014031227A JP 2014031227 A JP2014031227 A JP 2014031227A JP 6230443 B2 JP6230443 B2 JP 6230443B2
Authority
JP
Japan
Prior art keywords
general formula
icg
hyaluronic acid
peg
acid derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014031227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014185333A5 (enExample
JP2014185333A (ja
Inventor
康嗣 三木
康嗣 三木
達広 井上
達広 井上
靖人 小林
靖人 小林
克哉 中野
克哉 中野
浩一 大江
浩一 大江
文生 山内
文生 山内
矢野　哲哉
哲哉 矢野
南　昌人
昌人 南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canon Inc
Original Assignee
Canon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canon Inc filed Critical Canon Inc
Priority to JP2014031227A priority Critical patent/JP6230443B2/ja
Publication of JP2014185333A publication Critical patent/JP2014185333A/ja
Publication of JP2014185333A5 publication Critical patent/JP2014185333A5/ja
Application granted granted Critical
Publication of JP6230443B2 publication Critical patent/JP6230443B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014031227A 2013-02-22 2014-02-21 近赤外色素結合ヒアルロン酸誘導体およびそれを有する光イメージング用造影剤 Active JP6230443B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014031227A JP6230443B2 (ja) 2013-02-22 2014-02-21 近赤外色素結合ヒアルロン酸誘導体およびそれを有する光イメージング用造影剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013033633 2013-02-22
JP2013033633 2013-02-22
JP2014031227A JP6230443B2 (ja) 2013-02-22 2014-02-21 近赤外色素結合ヒアルロン酸誘導体およびそれを有する光イメージング用造影剤

Publications (3)

Publication Number Publication Date
JP2014185333A JP2014185333A (ja) 2014-10-02
JP2014185333A5 JP2014185333A5 (enExample) 2017-03-30
JP6230443B2 true JP6230443B2 (ja) 2017-11-15

Family

ID=50272677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014031227A Active JP6230443B2 (ja) 2013-02-22 2014-02-21 近赤外色素結合ヒアルロン酸誘導体およびそれを有する光イメージング用造影剤

Country Status (5)

Country Link
US (1) US9750827B2 (enExample)
EP (1) EP2958946B1 (enExample)
JP (1) JP6230443B2 (enExample)
CN (1) CN105008402B (enExample)
WO (1) WO2014129674A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245329B2 (en) * 2014-09-08 2019-04-02 Canon Kabushiki Kaisha Composition having dye and conjugate of polyethyleneglycol and additive and contrast agent for photoacoustic imaging having the same
WO2016060277A1 (en) 2014-10-16 2016-04-21 Canon Kabushiki Kaisha Polymer, and contrast agent for photoacoustic imaging, including the polymer
US10398788B2 (en) 2014-10-24 2019-09-03 Canon Kabushiki Kaisha Polymer and contrast agent for photoacoustic imaging including the polymer
KR20160142199A (ko) 2015-06-02 2016-12-12 삼성메디슨 주식회사 광음향 영상화를 위한 조영 조성물 및 그를 사용한 광음향 영상화하는 방법
JP2017002000A (ja) * 2015-06-12 2017-01-05 キヤノン株式会社 化合物又はその薬学的に受容可能な塩、及び、前記化合物又はその薬学的に受容可能な塩を有する光音響イメージング用造影剤。
US20180291123A1 (en) * 2015-09-04 2018-10-11 The Broad Of Regents Of The University Of Texas System Di-functionalized hyaluronic acid derivatives and hydrogels thereof
JP6789636B2 (ja) 2015-09-30 2020-11-25 キヤノン株式会社 重合体、前記重合体を有する光音響イメージング用造影剤
CN105596294B (zh) * 2015-12-21 2019-05-17 中国科学院深圳先进技术研究院 一种纳米靶向载药胶束及其制备方法和一种抗癌药物及其制备方法
CZ307511B6 (cs) * 2015-12-23 2018-10-31 Contipro A.S. Fluorescenční konjugát kyseliny hyaluronové nebo jeho sůl, hydrofobizovaný konjugát, způsoby jejich přípravy a použití
CN108884638B (zh) * 2016-03-22 2021-08-31 奥布专科学院 作为光学增白剂的多糖衍生物
AU2017300629B2 (en) * 2016-07-21 2019-11-07 Boston Scientific Scimed, Inc. Injectable compositions
CN106727314B (zh) * 2017-01-13 2021-01-01 中国药科大学 一种基于透明质酸的光敏剂／抗肿瘤药物自组装纳米递药系统的制备与表征
CN110431155A (zh) * 2017-04-07 2019-11-08 优瑞有限公司 低分子量透明质酸的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316007B1 (en) 1995-04-04 2001-11-13 Wound Healing Of Oklahoma Combined physical and immunotherapy for cancer
EP0820305A2 (en) 1995-04-04 1998-01-28 Wound Healing of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
US20030003048A1 (en) 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
JP2006025625A (ja) 2004-07-12 2006-02-02 Seikagaku Kogyo Co Ltd グリコサミノグリカン分解酵素の活性測定方法
US20080064954A1 (en) 2006-08-24 2008-03-13 Baylor College Of Medicine Method of measuring propulsion in lymphatic structures
ITMI20061726A1 (it) 2006-09-11 2008-03-12 Fidia Farmaceutici Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry
JP2009155486A (ja) 2007-12-27 2009-07-16 Kikkoman Corp 低分子化ヒアルロン酸とその製造法
EP2493458A2 (en) 2009-10-30 2012-09-05 The Ohio State University Multi-functional biodegradable particles for selectable targeting, imaging, and therapeutic delivery and use thereof for treating ocular disorders
HUE041616T2 (hu) 2010-01-28 2019-05-28 National Univ Corporation Mie Univ Indocianin vegyület, szintézisének eljárása, tisztítási eljárása, indocianin vegyületet alkalmazó diagnosztikai készítmény, és készülék in vivo kinetika mérésére és készülék keringés megjelenítésére a diagnosztikai készítmény alkalmazásával
JP2014129318A (ja) 2012-02-23 2014-07-10 Canon Inc インドシアニングリーン含有粒子、およびそれを有する光音響イメージング用造影剤
JP6195339B2 (ja) 2012-07-10 2017-09-13 キヤノン株式会社 粒子及び前記粒子を有する光音響用造影剤
WO2014013732A1 (en) 2012-07-20 2014-01-23 Canon Kabushiki Kaisha Compound and photoacoustic imaging contrast medium containing the compound
WO2014013729A1 (en) 2012-07-20 2014-01-23 Canon Kabushiki Kaisha Contrast agent for photoacoustic imaging
CN104470546B (zh) 2012-07-20 2018-02-27 佳能株式会社 化合物和含有所述化合物的光声成像造影剂

Also Published As

Publication number Publication date
CN105008402B (zh) 2018-09-18
EP2958946A1 (en) 2015-12-30
EP2958946B1 (en) 2020-09-09
US20150374856A1 (en) 2015-12-31
CN105008402A (zh) 2015-10-28
JP2014185333A (ja) 2014-10-02
US9750827B2 (en) 2017-09-05
WO2014129674A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
JP6230443B2 (ja) 近赤外色素結合ヒアルロン酸誘導体およびそれを有する光イメージング用造影剤
KR101847187B1 (ko) 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법
CN106727314B (zh) 一种基于透明质酸的光敏剂／抗肿瘤药物自组装纳米递药系统的制备与表征
KR101035269B1 (ko) 고분자 유도체-광감작제 복합체를 이용한 새로운 광역학치료제
Wang et al. Multi-stimuli responsive nanosystem modified by tumor-targeted carbon dots for chemophototherapy synergistic therapy
US10946109B2 (en) Polymer-type fluorescent molecule probe
CN106267241B (zh) 一种多功能多模态肿瘤特异性靶向相变型纳米微球光声造影剂及其应用
KR101419254B1 (ko) 효소 반응성 그라핀 옥사이드/생체 고분자-광감각제 나노복합체 및 이를 포함하는 형광 영상 진단 또는 광역학/광열 치료용 조성물
JP2002241307A (ja) 光増感剤を含有する超音波治療用活性酸素発生剤
WO2005095494A1 (ja) 新規水溶性フラーレン、その製造方法およびそれを含む活性酸素発生剤
KR101188979B1 (ko) 광역학 진단 또는 치료를 위한 생체 적합성 고분자와 광감작제의 결합체 및 이의 제조방법
KR101183732B1 (ko) 광역학 진단 또는 치료를 위한 아세틸화된 다당류 및 광감작제가 결합된 결합체 및 이의 제조방법
Wang et al. A gold nanostar based multi-functional tumor-targeting nanoplatform for tumor theranostic applications
CN113171342A (zh) 一种基于透明质酸的肿瘤靶向纳米胶束及其制备和应用
IT202000028445A1 (it) Nanosistema per la diagnosi ed il trattamento fototermico di tumori
Feng et al. Zwitterionic nanoparticles from indocyanine green dimerization for imaging-guided cancer phototherapy
CN116425728A (zh) 羧酸酯酶响应的诊疗一体化探针及其制备方法与应用
CN110354276B (zh) 一种前药及其制备方法和应用
Jeon et al. pH-Responsive hyaluronic acid-based nanocarrier for treatment of rheumatoid arthritis
CN106581691A (zh) 还原响应的靶向聚乙二醇‑聚碳酸酯美登素前药胶束、其制备方法与应用
CN113616806B (zh) 一种铂-艾考糊精-聚己内酯大分子化合物、纳米载药系统及其应用
CN102274002A (zh) 一种在位无损检测肿瘤的试剂盒及其制备方法
Kong et al. Novel biodegradable polymer tethered platinum (II) for photoacoustic imaging
CN118724755A (zh) 具有化学发光监控光控药物释放功能的纳米复合物及其制备方法和应用
CN119823356A (zh) 一种近红外光致半导体聚合物及其水解产物、侧链修饰聚合物、药物递送系统、光刺激响应纳米递送系统及制备方法和应用

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150903

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150903

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170919

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171017

R151 Written notification of patent or utility model registration

Ref document number: 6230443

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R151